Name the cardiometabolic disease, stage the fibrosis, and treat the risk that extends beyond the liver.
Reference image for orientation, not a diagnostic studySteatosis alone is not MASH; ballooning, inflammation, and especially fibrosis determine progression risk.Laboratory of Experimental Pathology, Division of Intramural Research, NIEHS (NIH) / Wikimedia Commons (Public domain). SourcePublic domain
Use MASLD and MASH terminology while distinguishing steatosis, steatohepatitis, and fibrosis.
Apply FIB-4 as a first-line risk assessment followed by appropriate secondary noninvasive testing.
The dashboard keeps injury pattern, function, complications, and next action visible together.
Quick check
A 55-year-old woman with type 2 diabetes, obesity, hypertension, and hepatic steatosis has platelets 118,000/mcL and mildly elevated ALT. She drinks little alcohol.
What is the most important next framing step?
The clinically decisive question is not simply whether fat exists, but whether advanced fibrosis is hiding beneath it.
Match weight-loss depth and fibrosis signal to clinical goals
Numbers are anchors, not substitutes for repeated assessment and patient-specific feasibility.
Weight loss of about 3% to 5% can reduce steatosis; more than 10% is often needed for high rates of MASH resolution and fibrosis improvement.
In many adults, FIB-4 below 1.3 indicates low risk for advanced fibrosis, while values at or above 1.3 prompt secondary testing; adults older than 65 often use a higher rule-in threshold of 2.0 for this pathway.
Patients with type 2 diabetes or multiple metabolic risks need periodic reassessment even after a low-risk FIB-4 because risk evolves.
Position each anchor from lower to higher concern or treatment intensity.
Terminology separates risk context from tissue injury
MASLD is a cardiometabolic disease definition; MASH adds steatohepatitis, and fibrosis stage drives liver outcomes.
MASLD requires hepatic steatosis plus at least one cardiometabolic risk factor, with alternative or additional etiologies considered rather than ignored.
MASH describes steatosis with hepatocellular ballooning and lobular inflammation, with or without fibrosis.
MetALD describes MASLD with alcohol intake above the MASLD range but below thresholds used for predominantly alcohol-associated disease; mixed etiologies can coexist.
Compare what each label actually establishes.
Fat is present in a cardiometabolic context, but steatohepatitis and advanced fibrosis are not automatically established.
Steatosis plus ballooning injury and inflammation; biopsy is the reference for histologic diagnosis.
Fibrosis adds prognostic weight, with stage 2 or 3 disease representing at-risk MASH in many treatment frameworks.
Advanced scar creates risks of portal hypertension, decompensation, and hepatocellular carcinoma.
Fibrosis stage predicts liver outcomes better than the amount of steatosis.
Use a two-step fibrosis pathway
Primary care can identify low-risk patients while routing indeterminate and high-risk patients to better tests and specialty care.
Confirm steatosis and cardiometabolic risk, quantify alcohol exposure, and evaluate other liver diseases when indicated.
Calculate FIB-4 from age, AST, ALT, and platelet count, recognizing lower accuracy in younger adults and age-related false positives in older adults.
Use vibration-controlled transient elastography, ELF, or another validated secondary test when FIB-4 is not low; refer when noninvasive tests suggest advanced fibrosis or results disagree.
Arrange the risk-stratification sequence.
Identify the at-risk populationType 2 diabetes, multiple metabolic risks, or imaging steatosis should trigger fibrosis assessment.
Apply FIB-4A low value can support follow-up in lower-acuity care; indeterminate or high values require more assessment.
Obtain secondary noninvasive testingLiver stiffness or ELF improves discrimination for advanced fibrosis.
Escalate discordant or high-risk resultsHepatology evaluation, and sometimes biopsy, resolves uncertainty that changes management.
Cardiovascular risk and liver risk must be treated together
Most patients carry major cardiometabolic risk even when liver disease has not yet decompensated.
Cardiovascular disease is a leading cause of death in MASLD, so blood pressure, lipids, diabetes, smoking, sleep apnea, and obesity deserve active management.
Statins are generally safe across the MASLD spectrum, including compensated cirrhosis, when otherwise indicated for cardiovascular risk reduction.
A normal aminotransferase value does not exclude MASH or advanced fibrosis, especially in patients with diabetes.
Choose the statement that should guide longitudinal care.
Treat cardiovascular risk aggressively while staging liver fibrosis.Correct: the care plan must address both competing and linked risks.
Avoid statins whenever hepatic steatosis is present.Incorrect: statins are generally safe and reduce cardiovascular risk when indicated.
Use ALT normalization as proof that fibrosis resolved.Incorrect: ALT does not reliably stage scar.
Assume steatosis alone predicts imminent liver failure.Incorrect: fibrosis stage is the stronger liver prognostic marker.
Follow disease from adipose tissue to zone 3 and the portal system
Excess fatty acid delivery and de novo lipogenesis increase hepatocyte triglyceride storage; lipotoxic stress can drive ballooning and inflammation.
MASH injury and perisinusoidal fibrosis often begin around zone 3 before bridging fibrosis connects vascular regions.
Cirrhotic architecture produces portal hypertension and creates a liver at risk for decompensation and hepatocellular carcinoma.
Place each clinical target on the disease map.
Weight loss and improved insulin sensitivity reduce substrate delivery and systemic risk.
Steatosis can progress to ballooning and inflammatory injury.
Zone 3 fibrosis can progress to bridging scar and cirrhosis.
Atherosclerotic risk may dominate mortality before liver decompensation.
Therapy begins with weight loss but no longer ends there
Lifestyle treatment is foundational, while current MASH therapy is selected by fibrosis stage, cirrhosis status, comorbidity, safety, and labeling.
A calorie deficit, Mediterranean-style dietary pattern, and regular aerobic plus resistance activity improve cardiometabolic health; greater sustained weight loss produces greater liver benefit.
Resmetirom and semaglutide 2.4 mg weekly have MASH indications for selected adults with noncirrhotic moderate-to-advanced fibrosis, consistent with F2-F3; neither indication should be generalized to isolated steatosis or decompensated cirrhosis.
Semaglutide can align MASH, obesity, diabetes, and cardiovascular goals in an eligible patient; other incretin or SGLT2 therapies should still be chosen for their approved metabolic or cardiorenal indications rather than treated as a class-wide MASH approval.
Reveal the proper role of each intervention.
Foundation for every stage; even modest loss improves steatosis, while larger sustained loss is usually needed for MASH and fibrosis improvement.
Build a durable plan, not a crash diet.
Has an accelerated-approval MASH indication for selected noncirrhotic F2-F3 disease and may also treat obesity and reduce cardiometabolic risk.
Verify contraindications and monitor response and tolerability.
Has an accelerated-approval MASH indication for selected adults with noncirrhotic F2-F3 disease and requires medication, thyroid, hepatic, and lipid review.
Do not extrapolate the indication to cirrhosis.
Use SGLT2 inhibitors, other incretin therapies, statins, and bariatric procedures for appropriate metabolic, cardiorenal, or obesity indications.
They complement rather than erase fibrosis-based liver care.
Stage 1 of 3: Overview
Overview
MASLD and MASH
Primary care can identify low-risk patients while routing indeterminate and high-risk patients to better tests and specialty care.
Step by step
Use a two-step fibrosis pathway
1Identify the at-risk populationType 2 diabetes, multiple metabolic risks, or imaging steatosis should trigger fibrosis assessment.
2Apply FIB-4A low value can support follow-up in lower-acuity care; indeterminate or high values require more assessment.
3Obtain secondary noninvasive testingLiver stiffness or ELF improves discrimination for advanced fibrosis.
4Escalate discordant or high-risk resultsHepatology evaluation, and sometimes biopsy, resolves uncertainty that changes management.
Clinical takeaway
Why it mattersUse vibration-controlled transient elastography, ELF, or another validated secondary test when FIB-4 is not low; refer when noninvasive tests suggest advanced fibrosis or results disagree.
RememberThe clinically decisive question is not simply whether fat exists, but whether advanced fibrosis is hiding beneath it.
Rounds question
Name today’s management pivot
Choose the clue that changes what the team does on this round.
What is the most important next framing step?
Key finding. A 55-year-old woman with type 2 diabetes, obesity, hypertension, and hepatic steatosis has platelets 118,000/mcL and mildly elevated ALT. She drinks little alcohol.
Answer. Recognize MASLD and assess advanced fibrosis risk rather than using ALT alone.
Why. Cardiometabolic steatosis fits MASLD, and thrombocytopenia raises concern for advanced fibrosis.
Board rule. The clinically decisive question is not simply whether fat exists, but whether advanced fibrosis is hiding beneath it.
Run the liver cases
A metabolic liver clinic separates steatosis from fibrosis risk and aligns treatment with cardiometabolic disease.
Cross out premature plans and highlight the finding that changes management. Each case separates injury, function, and complication.
A 44-year-old man with obesity, hypertension, triglycerides of 310 mg/dL, and ultrasound-confirmed steatosis rarely drinks alcohol. Viral hepatitis testing is negative.
Which diagnosis best uses current terminology?
Reason it through
What establishes the disease family?Hepatic steatosis plus cardiometabolic risk establishes MASLD.
What is not yet known?The presence of steatohepatitis and the fibrosis stage remain unknown.
What changes prognosis most?Assessment for advanced fibrosis.
MASLD names the context; it does not complete the staging.
What establishes the disease family?What is not yet known?
What establishes the disease family?Hepatic steatosis plus cardiometabolic risk establishes MASLD.
What is not yet known?The presence of steatohepatitis and the fibrosis stage remain unknown.
What changes prognosis most?Assessment for advanced fibrosis.
A 58-year-old woman with type 2 diabetes and steatosis has FIB-4 of 1.9. She has no decompensation and normal bilirubin.
What is the best next step for fibrosis assessment?
Reason it through
Why was FIB-4 useful first?It is inexpensive and helps rule out advanced fibrosis in many settings.
Why is 1.9 incomplete?It indicates a need for better discrimination rather than a final stage.
What does the second test add?Liver stiffness or ELF better estimates advanced fibrosis risk.
FIB-4 opens the second gate; it does not declare cirrhosis.
Why was FIB-4 useful first?Why is 1.9 incomplete?
Why was FIB-4 useful first?It is inexpensive and helps rule out advanced fibrosis in many settings.
Why is 1.9 incomplete?It indicates a need for better discrimination rather than a final stage.
What does the second test add?Liver stiffness or ELF better estimates advanced fibrosis risk.
A 61-year-old man with MASLD, type 2 diabetes, and prior myocardial infarction has LDL cholesterol of 154 mg/dL. His ALT is 72 U/L, and he has compensated advanced fibrosis without decompensation.
Which medication principle is most appropriate?
Reason it through
What is his immediate competing mortality risk?He has established atherosclerotic cardiovascular disease.
Does compensated fibrosis prohibit statins?No; statins are generally safe when clinically indicated.
What care model fits?Integrated cardiovascular, diabetes, obesity, and liver management.
Do not let liver fat distract from treating the artery that has already declared itself.
What is his immediate competing mortality risk?Does compensated fibrosis prohibit statins?
What is his immediate competing mortality risk?He has established atherosclerotic cardiovascular disease.
Does compensated fibrosis prohibit statins?No; statins are generally safe when clinically indicated.
What care model fits?Integrated cardiovascular, diabetes, obesity, and liver management.
A 49-year-old woman with obesity, biopsy-confirmed MASH, and stage 2 fibrosis has no cirrhosis and also has poorly controlled type 2 diabetes. She asks whether one medication can support weight, diabetes, and liver goals.
Which counseling best reflects current guidance?
Reason it through
What makes her liver disease clinically important?Stage 2 fibrosis places her beyond isolated steatosis.
Which current drug aligns all three goals?Semaglutide 2.4 mg weekly has a MASH indication and also treats obesity and diabetes in appropriate patients.
What does treatment not replace?Lifestyle care and ongoing fibrosis-based liver assessment.
Use one treatment plan to align metabolic and liver goals, but keep each outcome measurable.
What makes her liver disease clinically important?Which current drug aligns all three goals?
What makes her liver disease clinically important?Stage 2 fibrosis places her beyond isolated steatosis.
Which current drug aligns all three goals?Semaglutide 2.4 mg weekly has a MASH indication and also treats obesity and diabetes in appropriate patients.
What does treatment not replace?Lifestyle care and ongoing fibrosis-based liver assessment.
A 67-year-old man with MASH cirrhosis has platelets of 82,000/mcL and nodular liver morphology. His ALT is 31 U/L, and he has never undergone liver imaging surveillance.
What is the most appropriate next management principle?
Reason it through
Which fact controls management?Established cirrhosis.
Why is ALT unhelpful here?Aminotransferase level does not quantify portal hypertension or HCC risk.
What preventive pathway follows?HCC surveillance plus assessment and management of cirrhosis complications.
Once cirrhosis is present, surveillance follows the scar, not the ALT.
Which fact controls management?Why is ALT unhelpful here?
Which fact controls management?Established cirrhosis.
Why is ALT unhelpful here?Aminotransferase level does not quantify portal hypertension or HCC risk.
What preventive pathway follows?HCC surveillance plus assessment and management of cirrhosis complications.
Rapid review
Three questions to check
What is the most important next framing step?
Recognize MASLD and assess advanced fibrosis risk rather than using ALT alone.. Cardiometabolic steatosis fits MASLD, and thrombocytopenia raises concern for advanced fibrosis.
What establishes the disease family?
Hepatic steatosis plus cardiometabolic risk establishes MASLD.
What is not yet known?
The presence of steatohepatitis and the fibrosis stage remain unknown.
Resident physician and founding medical reviewer at Bone Wizardry, focused on clinical accuracy, clear diagnostic reasoning, and practical board-oriented teaching across the curriculum.
